Inhibition of tumor necrosis factor (TNF)-α is an effective treatment for Crohn disease. It is recommended as a second-line therapy in steroid-dependent or -refractory disease, although first-line treatment may improve chances of intestinal mucosal healing ([@B1]). In the context of diabetes, TNF-α has been implicated in the development of insulin resistance during obesity ([@B2]) and in autoimmune destruction of pancreatic β-cells in an animal model of type 1 diabetes ([@B3]), and a recent study demonstrated some preservation of insulin secretion in children with new-onset type 1 diabetes upon TNF-α inhibition ([@B4]).

Here, we report a case of a 29-year-old Caucasian man who was diagnosed with type 1 diabetes at the age of 27 years on the basis of rapid onset of hyperglycemia, a lean BMI of 22.7 kg/m^2^, signs of β-cell autoimmunity (autoantibodies to GAD 476 IU/mL \[normal value \<10\] and islet-cell autoantibodies 125 units/mL \[normal value \<1.5\]), and a negative family history of diabetes. Upon treatment with insulin glargine and insulin lispro, A1C levels decreased from 9.4% (79 mmol/mol) to 6.1% (43 mmol/mol) within 6 months. In parallel to the diagnosis of type 1 diabetes, the patient reported intermittent feelings of abdominal fullness and subsequent diarrhea. Fecal calprotectin levels were found to be markedly elevated: up to 1,280.6 μg/g (normal value \<50 μg/g stool), and Crohn disease was histologically confirmed 9 months after the diagnosis of type 1 diabetes.

To prevent worsening of diabetes upon steroid therapy and because of the putative role of TNF-α in β-cell demise, we decided to treat the patient with the TNF-α inhibitor infliximab. Infliximab (5 mg/kg body wt) was administered intravenously at weeks 0, 2, and 6 and every 8 weeks thereafter ([@B1]). After the first dose of infliximab, 9 months after diagnosing type 1 diabetes, remission of Crohn disease was achieved as reflected by normalization of bowel movements and by fecal calprotectin levels that were below the normal range (\<50 μg/g stool) after the second dose of infliximab. High-sensitivity C-reactive protein levels decreased from 1.3 mg/L (normal value \<10) to \<0.3 mg/L after the first dose of infliximab was administered.

Remission of Crohn disease was paralleled by an immediate and sustained 2.4-fold increase in insulin secretion ([Fig. 1*A*](#F1){ref-type="fig"}) and a progressive up to 6.9-fold decrease in insulin resistance ([Fig. 1*B*](#F1){ref-type="fig"}) as derived from measurements of glucose and C-peptide assessed during mixed-meal tests that were performed right before and after the initiation of infliximab therapy every 3--4 months over a 1-year period. A1C remained ∼6.0% (42 mmol/mol), while insulin lispro requirements per 10 g carbohydrate dropped from 0.8 to 0.5 units after initiation of infliximab treatment.

![Response to infliximab therapy in a patient with Crohn disease and type 1 diabetes. *A*: C-peptide secretion index during mixed-meal test before and after initiation of infliximab {C-peptide secretion index = \[(plasma C-peptide at 30 min of mixed-meal test) -- (fasting plasma C-peptide)\]/fasting plasma glucose}. *B*: Whole-body sensitivity index during mixed-meal test before and after start of infliximab therapy \[whole-body sensitivity index = 10,000/√(fasting plasma glucose × fasting plasma C-peptide × mean mixed-meal test plasma glucose × mean mixed-meal test plasma C-peptide)\]. Apr., April; Mar., March; Jun., June; Oct., October.](e90fig1){#F1}

Several mechanisms may explain the observed effects of TNF-α antagonism on glucose metabolism. Since the treatment with infliximab was initiated 9 month after the diagnosis of diabetes, at a time when the patient had a stable requirement of insulin and A1C was ∼6%, a reversal due to "honeymoon" or glucotoxicity is unlikely. Thus, it is conceivable that insulin secretion may have improved as a direct result of the immunosuppressive effects on insulitis and enhanced insulin sensitivity may have alleviated the burden on the β-cells. Of note, it was not expected to see changes in insulin sensitivity in a patient with type 1 diabetes. However, in the case depicted herein, increased leakiness of the mucosal barrier for bacterial products or systemic inflammation due to Crohn disease may have promoted insulin resistance ([@B5]). Independently of the underlying mechanisms, we propose that TNF-α inhibitors be considered a first-line treatment in patients with both type 1 diabetes and Crohn disease.
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